Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline
- PMID: 19207169
- DOI: 10.1111/j.1423-0410.2008.01143.x
Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline
Abstract
Background and objectives: IgPro10 (Privigen) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with 250 mM L-proline at pH 4.8. A 3-year study was performed to assess its stability.
Materials and methods: Physicochemical, biological and immunological parameters of Privigen were assessed during storage under controlled conditions over up to 36 months at 25 degrees C.
Results: Privigen was shown to be stable after storage for 3 years at room temperature (25 degrees C). Of all parameters tested, only a few showed changes during storage. The appearance of the solution complied with the specifications given by the European Pharmacopeia over the full study period, with a single exception. The IgG fraction in Privigen displayed high purity (> or = 98%), which did not change during storage over 36 months. No relevant amounts of aggregated IgG molecules were formed in Privigen samples and the ratio between monomers and dimers shifted slightly towards the equilibrium over time. Testing of reference antibody contents and the Fc function demonstrated that the biological activity and effector functions of Privigen were preserved over the full study period of 36 months.
Conclusion: Thirty-six months room temperature stability of Privigen was achieved at pH 4.8 with an innovative formulation containing the physiological stabilizer L-proline.
Similar articles
-
L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.Biologicals. 2010 Jan;38(1):150-7. doi: 10.1016/j.biologicals.2009.09.002. Biologicals. 2010. PMID: 19931468
-
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.Immunotherapy. 2011 Feb;3(2):163-76. doi: 10.2217/imt.10.108. Immunotherapy. 2011. PMID: 21322757
-
Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration.Biologicals. 2011 Jan;39(1):43-9. doi: 10.1016/j.biologicals.2010.11.004. Epub 2011 Jan 22. Biologicals. 2011. PMID: 21257320
-
Safety of L-proline as a stabilizer for immunoglobulin products.Expert Rev Clin Immunol. 2012 Feb;8(2):169-78. doi: 10.1586/eci.11.97. Expert Rev Clin Immunol. 2012. PMID: 22288455 Review.
-
IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product.Int Immunopharmacol. 2006 Apr;6(4):517-22. doi: 10.1016/j.intimp.2005.11.005. Epub 2005 Dec 13. Int Immunopharmacol. 2006. PMID: 16504913 Review.
Cited by
-
Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.J Clin Immunol. 2014 Oct;34(7):804-12. doi: 10.1007/s10875-014-0070-z. Epub 2014 Jul 1. J Clin Immunol. 2014. PMID: 24981039 Free PMC article.
-
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.Biol Ther. 2014 Dec;4(1-2):15-26. doi: 10.1007/s13554-014-0016-2. Epub 2014 May 20. Biol Ther. 2014. PMID: 24841428 Free PMC article.
-
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21553933 Clinical Trial.
-
Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.J Clin Immunol. 2010 May;30(3):442-8. doi: 10.1007/s10875-010-9373-x. Epub 2010 Mar 10. J Clin Immunol. 2010. PMID: 20217199 Clinical Trial.
-
Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies.J Biol Chem. 2013 Feb 8;288(6):4085-94. doi: 10.1074/jbc.M112.410811. Epub 2012 Dec 18. J Biol Chem. 2013. PMID: 23250751 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources